| ORIGINAL ARTICLE |
|
|
|
|
|
| Year : 2020 | Volume
: 62
| Issue : 6 | Page : 697-702 |
Tapentadol, the new kid on the block in India: Is it time to worry?
Debasish Basu1, Tathagata Mahintamini1, Abhishek Ghosh1, Fazle Roub1, BN Subodh1, SK Mattoo2, Ajit Avasthi2
1 Department of Psychiatry, Drug De.Addiction and Treatment Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India
2 Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Correspondence Address:
Dr. Abhishek Ghosh
Department of Psychiatry, Drug De-addiction and Treatment Centre, Postgraduate Institute of Medical Education and Research, Chandigarh
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/psychiatry.IndianJPsychiatry_332_20
Background and Objectives: Large-scale prospective case series of tapentadol abuse or dependence in India is not available. Hence, we aimed to study the prevalence and profile of tapentadol users in a treatment-seeking population.
Materials and Methods: The study had prospective and retrospective arms. We collected 8-month prospective data by face-to-face interviews (n = 70) and 8-year retrospective data from case notes (n = 26) with either tapentadol misuse/abuse or dependence in patients attending a de-addiction center.
Results: The prevalence of tapentadol abuse or dependence was 25% among the pharmaceutical opioid users. Concurrent use of other opioids was seen in >80% of participants of both the arms. Major sources of tapentadol were chemists (without a prescription) (53%) and doctors (prescriptions) (40%). Patients in the tapentadol dependence group had a significantly higher dose, duration, and pharmaceutical opioid use.
Conclusion: India needs awareness promotion, training, availability restriction, and provision of treatment for tapentadol abuse or dependence.
[FULL TEXT] [PDF]*
|
